Jobs
-
The Pulmonary-Allergy Drugs Advisory Committee (PADAC) of the US FDA has voted to recommend approval of the 75 mcg dose of Novartis’s QAB149 indacaterol dry powder formulation for the treatment of COPD but has voted… Read more . . .
-
After a favorable end-of-Phase 2 meeting with the FDA, St. Renatus has announced that it plans to proceed to Phase 3 studies of its dental anesthetic, which is delivered as a nasal mist via a… Read more . . .
-
On March 31, 2011, 150-200 prospective buyers will gather in a Beaux Arts ballroom in New York City for ICAP Ocean Tomo’s Spring 2011 Live Auction. After having attended a welcome dinner the previous night… Read more . . .
-
AstraZeneca has announced that it will stop manufacturing the Pulmicort 100 and 200 µg/dose budesonide HFA pMDI. According to the company, the device has caused “complex manufacturing issues” and the resulting difficulty is causing it… Read more . . .
-
Briefing materials prepared by the FDA for the Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting scheduled for March 8, 2011 ask committee members to consider the safety of the higher dose of Novartis’s indacaterol inhalation powder.… Read more . . .
-
German biopharmaceutical company Revotar has announced that its Bimosiamose inhalation solution for the treatment of COPD met its primary endpoint in a Phase 2 study involving more than 75 patients with moderate-to-severe COPD. Bimosiamose is… Read more . . .
-
Freeman Technology will offer the new Graphical User Interface (GUI) for its FT4 powder rheometer instrument with all new instruments, and it will be available as a free upgrade for current owners. The FT4 provides… Read more . . .
-
The COPD Foundation has announced that COPD: Journal of Chronic Obstructive Pulmonary Disease will be its official journal. According to John W Walsh, President of the COPD Foundation, “COPD: Journal of Chronic Obstructive Pulmonary Disease,… Read more . . .
-
Biopharmaceutical company Insmed Incorporated has announced that its shareholders have approved a one-for-ten reverse stock split and the conversion of its Series B preferred stock into common stock. Insmed acquired Transave and its Arikace inhaled… Read more . . .
-
Submit poster and paper abstracts by May 27, 2011 to info@apsgb.org. See abstract guidelines (link opens Word document). Five £100 prizes will be awarded. Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.